natgillin/translations-raw huggingface dataset:
BILAG I LISTE OVER NAVNE, LÆGEMIDDELFORMER, STYRKER PÅ LÆGEMIDLERNE, INDGIVELSESVEJ, INDEHAVERE AF MARKEDSFØRINGSTILLADELSEN I MEDLEMSLANDENE 
List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states
Oral suspension Oral anvendelse 
Oral suspension Oral use
Storbritannien Line Range Limited, c/o Orbis consumer products Limited, 
Line Range Limited, c/o Orbis consumer products Limited,
Storbritannien Bell Sons & Company Druggist limited. 
Bell Sons & Company Druggist limited.
Storbritannien LPC Medical (UK) Limited, 2 Covent Garden Close, Luton, 
LPC Medical (UK) Limited, 2 Covent Garden Close, Luton,
Storbritannien Ayrton Saunders Limited, North Way, 
Ayrton Saunders Limited, North Way,
Storbritannien Novartis Consumer Health UK Limited, 
Novartis Consumer Health UK Limited,
Slovenien Alkaloid d.o.o., Slandrova ulica 4, Ljubljana 1231, 
Alkaloid d.o.o., Slandrova ulica 4, Ljubljana 1231, Slovenia
Belgium pholcodin 0,12 g 
Belgium pholcodine 0,12 g
Storbritannien Pinewood Laboratories Limited, 
Pinewood Laboratories Limited,
Caltoson Balsamico Tablet 
Caltoson Balsamico Tablets
EX17 3AP, 
EX17 3AP, United Kingdom
Storbritannien Thornton & Ross Limited, Linthwaite, 
Thornton & Ross Limited, Linthwaite,
Slaidburn Crescent, Southport, 
Gifford House, Slaidburn Crescent, Southport, Mersyside,
Day Nurse Capsules Kapsel, hård 
Day Nurse Capsules Capsule, hard Oral use
B12 9DR, 
Birmingham, B12 9DR,
Luxembourg Eurogenerics S.A. ESPLANADE HEYSEL, B.22 1020 BRUXELLES Belgium phenylephrinhydrochlori d 
Luxembourg Eurogenerics S.A. ESPLANADE HEYSEL, B.22 1020 BRUXELLES Belgium
Avonbridge House, 
Avonbridge House, Bath Road,
9830 Sint-Martens-Latem Belgium pholcodin 5 mg/5ml Doxylaminsuccinat 5 mg/5ml 
9830 Sint-Martens-Latem Belgium pholcodine 5 mg/5ml Doxylaminii succinas 5 mg/5ml
Belgium doxylamin pholcodin benzoesyre sulfogaiacol 
Belgium doxylamine pholcodine benzoate sodique sulfogaiacol
LU4 8QB, 
Bedfordshire, LU4 8QB,
West Yorkshire, HD7 5QH, 
Huddersfield, West Yorkshire, HD7 5QH
Storbritannien Beecham Group PLC, 980 Great West Road, Brentford, 
Beecham Group PLC, 980 Great West Road, Brentford,
Diagonal, 67-69 Barcelona 08019 Spain pholcodin ; cineol ; 
Diagonal, 67-69 Barcelona 08019 Spain pholcodine ; cineol ; cherry laurel water ; menthol ; terpineol ; benzocaine
pholcodin ; sulfogaiacol 
pholcodine ; sulfogaïacol
Cunard Road, 
Cunard Road, Park Royal,
Storbritannien Wise Pharmaceuticals Limited, 
Wise Pharmaceuticals Limited,
Storbritannien Alliance Pharmaceuticals Limited, 
Alliance Pharmaceuticals Limited,
Storbritannien Sterling Pharmaceuticals Limited, 
Sterling Pharmaceuticals Limited,
Belgium camphre eucalyptol gaiacol phenol pholcodin 
Belgium camphre eucalyptol gaiacol phenol pholcodine
RH12 5AB, 
West Sussex, RH12 5AB,
0.1%w/w Bell Pholcodine Linctus Oral væske 
0.1%w/w Bell Pholcodine Linctus Oral liquid
Belgium pholcodin thiophencarboxylat eucalyptol, æterisk olie methylparahydroxybenz oat parahydroxybenzoate de propyle 
Belgium pholcodine thiophene carboxylate eucalyptus huile essentielle parahydroxybenzoate de methyle parahydroxybenzoate de propyle
8560 Wevelgem Belgium pholcodin 15 mg/15ml Sulfogaiacol 300 mg/15ml 
Belgium pholcodine 15 mg/15ml Sulfogaiacol 300 mg/15ml
Co Tipperary, 
Co Tipperary, Ireland
Pseudoephedrin 
Pseudoephedrine
myrte (æterisk olie); alpha-terpineol ; pholcodin 
myrte (huile essentielle de) (deterpenee) ; alpha-terpinéol ; pholcodine
Pholcodin, Chlorphenamin, Biclotymol 
Pholcodine, Chlorphenamine, Biclotymol
pholcodin ; Erysimum (tør ekstrakt) 
pholcodine ; érysimum (extrait sec d')
Ballymacarbry, 
Ballymacarbry, Clonmel,
Kalii guaiacolsulfonas47,5 mg/5ml 
Kalii guaiacolsulfonas 47,5 mg/5ml Natrii benzoas 50 mg/5ml
biclotymol ; cineol ; pholcodin 
biclotymol ; cinéole ; pholcodine
7 Oxford Street, 
7 Oxford Street, Manchester, M1 4PB,
Storbritannien The Boots company PLC, 1 Thane Road West, 
The Boots company PLC, 1 Thane Road West, Nottingham,
Chippenham, 
Chippenham, Wiltshire,
Pholcodin, Chlorphenamin, Biclotymolm 
Pholcodine, Chlorphenamine, Biclotymolm
Promethazine Hydrochloride, Paracetamol, Dextromethorphanhydr obromid 
Promethazine Hydrochloride, Paracetamol, Dextromethorphan hydrobromide Pholcodine;
8560 Wevelgem Belgium pholcodin eucalyptolum camphora synthetica gaiacolum phenolum 
Belgium pholcodine eucalyptolum camphora syntheticum gaiacolum phenolum
Diphenhydraminhydroc hlorid ; Paracetamol ; Ethanol 
Diphenhydramine Hydrochloride ; Paracetamol ;
Pholcodine Linctus BP. Oral opløsning Oral anvendelse 
Pholcodine Linctus BP Oral solution
cineol ; pholcodin 
guaïfénésine ; pholcodine
Ephedrinhydrochlorid, Chlorphenamin Maleate 
Pholcodine, Ephedrine Hydrochloride, Chlorphenamine Maleate
Pseudoephedrin hydrochloride 
Pseudoephedrine hydrochloride
Erysimum (flydende ekstrakt) ; pholcodin 
erysimum (sommite fleurie d') (extrait fluide de) ; pholcodine
Myrte (æterisk olie); ; pholcodin 
MYRTE (huile essentielle de) (deterpenee) ; pholcodine
biclotymol ; chlorphenaminmaleat ; pholcodin 
biclotymol ; chlorphénamine (maléate de) ; pholcodine
Pholcodin; Paracetamol; diphenhydramine hydrochloride; 
Paracetamol; diphenhydramine hydrochloride;
Diphenhydramine Pseudoephedrin Hydrochloride 
Diphenhydramine Psedoephedrine Hydrochloride
Erysimum (tør ekstrakt) Pholcodin 
Erysimum extr.sec Pholcodine
Paracetamol Pseudoephedrin Hydrochloride Pholcodin 
Paracetamol Pseudoephedrine Hydrochloride Pholcodine
Storbritannien Ernest Jackson and company Limited, 
Ernest Jackson and company Limited, 29 High Street, Crediton,
Pseudoephedrin Hydrochloride ; Pholcodin ; 
Pseudoephedrine Hydrochloride ; Pholcodine
Paracetamol, Pseudoephedrin hydrochloride, Pholcodin 
Paracetamol, Pseudoephedrine hydrochloride, Pholcodine
Promethazinhydrochlori d Pholcodin 
Promethazine Hydrochloride ; Pholcodine
Pseudoephedrin Hydrochloride ; 
Psedoephedrine Hydrochloride ;
pholcodin ; natrii benzoas 
pholcodine ; sodium (benzoate de)
PPS = pr. protokol-sæt 
PPS = per protocol set
Hold ikke op med at tage Vipidia uden at kontakte din læge først. 
Do not stop taking Vipidia without consulting your doctor first.
Lægen fortæller dig, hvis du skal ændre mængden af andre lægemidler, som du tager. 
Your doctor will tell you if you need to change the amount of other medicines you take.
Det er vigtigt, at du bliver ved med at tage den anden diabetesmedicin og fortsat følger de råd om kost og motion, som din sygeplejerske eller læge har givet dig. 
It is important that you continue to take your other anti-diabetic medicine, and continue to follow the advice on diet and exercise that your nurse or doctor has given you.
Vipidia skal tages én gang dagligt med eller uden mad. 
Vipidia should be taken once daily with or without food.
Alogliptins absolutte biotilgængelighed er ca. 100 %. 
The absolute bioavailability of alogliptin is approximately 100%.
FAS = fuldt analysesæt 
FAS = full analysis set
MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/13/844/001-030 
MARKETING AUTHORISATION NUMBER(S) EU/1/13/844/001-030
Kombination med andre antidiabetiske lægemidler 
Combination with other anti-diabetic medicinal products
Din læge vil hjælpe dig med at beslutte, om du skal fortsætte med at amme eller fortsætte med at bruge Vipidia. 
Your doctor will help you to decide whether to continue breast-feeding or to continue using Vipidia.
Hvis du har glemt at tage en dosis, skal du tage den, så snart du kommer i tanke om det. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. 
If you forget to take a dose, take it as soon as you remember it. Do not take a double dose to make up for a forgotten dose.
STOP med at tage Vipidia, og kontakt lægen med det samme, hvis du får en eller flere af følgende alvorlige bivirkninger: 
STOP taking Vipidia and contact a doctor immediately if you notice any of the following serious side effects:
Det kan være 12,5 mg eller 6,25 mg én gang dagligt, afhængigt af sværhedsgraden af din nyresygdom. 
This may be 12.5 mg or 6.25 mg once a day, depending on the severity of your kidney disease.
Dit blodsukker kan blive højere, når du holder op med at tage Vipidia. 
Your blood sugar levels may increase when you stop taking Vipidia.
Vipidia virker ved at øge insulinniveauet i kroppen efter et måltid og derved sænke mængden af sukker i kroppen. 
Vipidia works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body.
Alder (65-81 år), køn, race (hvid, sort og asiatisk) og kropsvægt havde ingen klinisk relevant indvirkning på alogliptins farmakokinetik. 
Age (65-81 years old), gender, race (white, black and Asian) and body weight did not have any clinically relevant effect on the pharmacokinetics of alogliptin.
Det bruges til at sænke blodsukkeret hos voksne med type 2-diabetes. 
It is used to lower blood sugar levels in adults with type 2 diabetes.
Alogliptins indvirkning på fertiliteten hos mennesker er ikke undersøgt. 
The effect of alogliptin on fertility in humans has not been studied.
Alogliptin var ikke karcinogent i de 2-årige karcinogenicitetsstudier, der blev udført på rotter og mus. 
Alogliptin was not carcinogenic in 2-year carcinogenicity studies conducted in rats and mice.
Din læge vil ordinere Vipidia sammen med et eller flere andre lægemidler til styring af dit blodsukker. 
Your doctor will prescribe Vipidia together with one or more other medicines to control your blood sugar levels.
Endvidere indikerer de kliniske data ingen interaktion med p-glykoproteinhæmmere eller -substrater. 
Furthermore, clinical data do not suggest interaction with p-glycoprotein inhibitors or substrates.
Der er ikke fastslået nogen kausal sammenhæng. 
A causal relationship has not been established.
Hvis du har en nyresygdom, kan din læge ordinere en lavere dosis. 
If you have kidney disease your doctor may prescribe you a reduced dose.
Hvis du har taget flere tabletter, end du skulle, eller hvis en anden person, f.eks. et barn, tager dine tabletter, skal du kontakte læge eller søge til den nærmeste skadestue med det samme. 
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away.
Hos raske personer havde alogliptin ingen indvirkning på prothrombin-tid eller INR (International Normalised Ratio), når det blev administreret samtidigt med warfarin. 
In healthy subjects, alogliptin had no effect on prothrombin time or International Normalised Ratio (INR) when administered concomitantly with warfarin.
Vipidia må ikke gives til patienter med type 1-diabetes mellitus eller anvendes til behandling af diabetisk ketoacidose. 
Vipidia should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.
Erfaringen med brug af alogliptin i kliniske studier med patienter med kongestiv hjerteinsufficiens NYHA (New York Heart Association)-klasse III og IV er begrænset, og forsigtighed anbefales hos disse patienter. 
Experience of alogliptin use in clinical studies in patients with congestive heart failure of New York Heart Association (NYHA) functional class III and IV is limited and caution is warranted in these patients.
Det anbefales, at nyrefunktionen vurderes inden igangsættelse af behandlingen og regelmæssigt herefter (se pkt. 
Appropriate assessment of renal function is recommended prior to initiation of treatment and periodically thereafter (see section 4.4).
Dette lægemiddel anbefales ikke til patienter med svært nedsat leverfunktion, da der ikke findes tilstrækkelige data for denne patientgruppe. 
This medicine is not recommended for patients with severely reduced liver function due to the lack of data in these patients.
I kliniske studier med alogliptin blev anafylaktiske reaktioner indberettet med en lav forekomst. 
In clinical studies of alogliptin, anaphylactic reactions were reported with a low incidence.
Immunsystemet overfølsomhed ikke kendt 
Immune system disorders hypersensitivity not known
Nervesystemet hovedpine almindelig 
Nervous system disorders headache common
Vipidia kan ikke erstatte insulin hos patienter med insulinkrævende diabetes. 
Vipidia is not a substitute for insulin in insulin-requiring patients.
Yderligere oplysninger om Vipidia findes på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu. 
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
I disse studier var 2.257 af de alogliptin-behandlede patienter ≥ 65 år, og 386 af de alogliptin-behandlede patienter var ≥ 75 år. 
In these studies, 2,257 alogliptin-treated patients were ≥ 65 years old and 386 alogliptin-treated patients were ≥ 75 years old.
Alogliptin blev elimineret med en gennemsnitlig terminal halveringstid (T1/2) på ca. 21 timer. 
Alogliptin was eliminated with a mean terminal half-life (T1/2) of approximately 21 hours.
Sikkerhedsprofilen for alogliptin var den samme hos ældre (≥ 65 år) og personer under 65 år. 
The safety of alogliptin between the elderly (≥ 65 years old) and non-elderly (< 65 years old) was similar.
Det er ukendt, om alogliptin udskilles i human mælk. 
It is unknown whether alogliptin is excreted in human milk.
Vipidia anbefales ikke til børn og unge under 18 år, da der ikke foreligger tilstrækkelige data for denne aldersgruppe. 
Vipidia is not recommended for children and adolescents under 18 years due to the lack of data in these patients.
Der var 703 patienter, som oplevede en hændelse inden for det sekundære sammensatte MACEendepunkt (første hændelse af kardiovaskulær død, ikke-dødeligt myokardieinfarkt, ikke-dødeligt apopleksi og akut revaskularisering på grund af ustabil angina). 
There were 703 patients who experienced an event within the secondary MACE composite endpoint (first event of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and urgent revascularization due to unstable angina).
Mikrokrystallinsk cellulose Hydroxypropylcellulose Croscarmellosenatrium Magnesiumstearat 
Hydroxypropylcellulose Croscarmellose sodium Magnesium stearate
Den samlede eksponering (AUC(0-inf)) for alogliptin efter administration af en enkeltdosis svarede til eksponeringen i løbet af ét dosisinterval (AUC(0-24)) efter 6 dage med administration én gang dagligt. 
Total exposure (AUC(0-inf)) to alogliptin following administration of a single dose was similar to exposure during one dose interval (AUC(0-24)) after 6 days of once daily dosing.
(Patienter med nyresygdom i slutstadiet fik hæmodialyse umiddelbart efter dosis med alogliptin. 
(Patients with end-stage renal disease underwent haemodialysis immediately after alogliptin dosing.
Vipidia indeholder: - Aktivt stof: alogliptin. 
What Vipidia contains - The active substance is alogliptin.
Vipidia kan derfor tages med eller uden mad. 
Vipidia may, therefore, be administered with or without food.
Den hyppigste bivirkning hos patienter, der blev behandlet med 25 mg alogiptin, var hovedpine. 
The most common adverse reaction in patients treated with 25 mg alogliptin was headache.
Du kan tage dette lægemiddel alene eller sammen med et måltid. 
You can take this medicine with or without food.
Den samlede eksponering for alogliptin var ca. 10 % lavere, og den højeste eksponering var ca. 8 % lavere hos patienter med moderat nedsat leverfunktion sammenlignet med raske forsøgspersoner. 
Total exposure to alogliptin was approximately 10% lower and peak exposure was approximately 8% lower in patients with moderate hepatic impairment compared to healthy control subjects.
Type 2diabetes kaldes også ikke-insulinkrævende diabetes mellitus eller gammelmandssukkersyge. 
Type 2 diabetes is also called non-insulin-dependent diabetes mellitus or NIDDM.
Pakningsstørrelser med 10, 14, 28, 30, 56, 60, 84, 90, 98 eller 100 filmovertrukne tabletter. 
Pack sizes of 10, 14, 28, 30, 56, 60, 84, 90, 98 or 100 film-coated tablets.
Hvis der er mistanke om akut pancreatitis, skal behandlingen med Vipidia afbrydes, og hvis mistanken bekræftes, må behandlingen med Vipidia ikke genoptages. 
If pancreatitis is suspected, Vipidia should be discontinued; if acute pancreatitis is confirmed, Vipidia should not be restarted.
Ikke-dødelig apopleksi *Samlet var der 153 forsøgspersoner (5,7 %) i alogliptin-gruppen og 173 forsøgspersoner (6,5 %) i placebogruppen, som døde (mortalitet af enhver årsag). 
Nonfatal Stroke *Overall there were 153 subjects (5.7%) in the alogliptin group and 173 subjects (6.5%) in the placebo group who died (all-cause mortality).
Hud og subkutane væv pruritus almindelig udslæt almindelig eksfoliative hudsygdomme, herunder Stevens-Johnsons syndrom erythema multiforme ikke kendt ikke kendt angioødem ikke kendt urticaria ikke kendt 
Skin and subcutaneous tissue disorders pruritus common rash common exfoliative skin conditions including Stevens-Johnson syndrome erythema multiforme not known not known angioedema not known urticaria not known
Da distributionen af AUC-værdier for alogliptin hos disse patienter imidlertid var inden for det samme område som for kontrolpersonerne, er det ikke nødvendigt med dosisjustering hos patienter med let nedsat nyrefunktion (se pkt. 
However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment for patients with mild renal impairment is necessary (see section 4.2).
Vipidia tages, når dit blodsukker ikke kan styres godt nok gennem kost, motion og din anden diabetesmedicin. 
Vipidia is taken when your blood sugar cannot be adequately controlled by diet, exercise and one or more of these other oral anti-diabetic medicines.
Det Europæiske Lægemiddelagentur har udsat forpligtelsen til at fremlægge resultaterne af studier med Vipidia i en eller flere undergrupper af den pædiatriske population med type 2-diabetes mellitus (se pkt. 
The European Medicines Agency has deferred the obligation to submit the results of studies with Vipidia in one or more subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use).
Shellac Sort jernoxid (E172) 
Shellac Iron oxide black (E172)
Det skal besluttes, om amning skal ophøre eller behandling med alogliptin seponeres, idet der tages højde for fordelene ved amning for barnet i forhold til de terapeutiske fordele for moderen. 
A decision on whether to discontinue breast-feeding or to discontinue alogliptin therapy should be made taking into account the benefit of breast-feeding for the child and the benefit of alogliptin therapy for the woman.
Der blev fundet to mindre metabolitter efter administration af en oral dosis [14C]-alogliptin: N-demethyleret alogliptin, M-I (< 1 % af moderstoffet) og N-acetyleret alogliptin, M-II (< 6 % af moderstoffet). 
Two minor metabolites were detected following administration of an oral dose of [14C] alogliptin, N-demethylated alogliptin, M-I (< 1% of the parent compound), and N-acetylated alogliptin, M-II (< 6% of the parent compound).
(tosidet 95 %-KI) 
(2-sided 95% CI)
Hvis du holder op med at tage Vipidia 
If you stop taking Vipidia
Sikkerheden ved og virkningen af Vipidia hos børn og unge under 18 år er endnu ikke klarlagt. 
The safety and efficacy of Vipidia in children and adolescents < 18 years old have not been established.
Vipidia fås i blisterpakninger med 10, 14, 28, 30, 56, 60, 84, 90, 98 eller 100 tabletter. 
Vipidia is available in blister packs containing 10, 14, 28, 30, 56, 60, 84, 90, 98 or 100 tablets.
Primært sammensat endepunkt [første hændelse af KV- død, ikkedødeligt MI og ikke-dødelig apopleksi] 
Primary Composite Endpoint [First Event of CV Death, Nonfatal MI and Nonfatal Stroke]
Studierne omfattede 5.744 patienter med let nedsat nyrefunktion, 1.290 patienter med moderat nedsat nyrefunktion og 82 patienter med svært nedsat nyrefunktion/terminalt nyresvigt, der blev behandlet med alogliptin. 
The studies included 5,744 patients with mild renal impairment, 1,290 patients with moderate renal impairment and 82 patients with severe renal impairment / end-stage renal disease treated with alogliptin.
For en sikkerheds skyld bør alogliptin undgås under graviditet. 
As a precautionary measure, it is preferable to avoid the use of alogliptin during pregnancy.
Niveauet uden observeret negativ effekt (NOAEL) i toksicitetsstudier med gentagen dosering hos rotter og hunde, som varede op til henholdsvis 26 og 39 uger, viste eksponeringsmargener, der var henholdsvis ca. 147 og 227 gange større end eksponeringen hos mennesker, der tager den anbefalede daglige dosis på 25 mg alogliptin. 
The no-observed-adverse-effect level (NOAEL) in the repeated dose toxicity studies in rats and dogs up to 26 and 39 weeks in duration, respectively, produced exposure margins that were approximately 147- and 227-fold, respectively, the exposure in humans at the recommended dose of 25 mg alogliptin.
Vipidia påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner. 
Vipidia has no or negligible influence on the ability to drive and use machines.
I et klinisk studie med alogliptin givet som enkeltstofbehandling var forekomsten af hypoglykæmi på samme niveau som for placebo, og den var lavere end for placebo i et andet studie med alogliptin som tillæg til sulfonylurinstof. 
In a clinical study of alogliptin as mono-therapy, the incidence of hypoglycaemia was similar to that of placebo, and lower than placebo in another study as add-on to a sulphonylurea.
Bivirkninger med ukendt hyppighed (hyppigheden kan ikke bestemmes ud fra de foreliggende data): 
Not known (frequency cannot be estimated from the available data): - An allergic reaction.
Overfølsomhedsreaktioner, herunder anafylaktiske reaktioner, angioødem og eksfoliative hudreaktioner inklusive Stevens-Johnsons syndrom og erythema multiforme, er observeret for DPP-4hæmmere og er spontant indberettet for alogliptin efter markedsføring. 
Hypersensitivity reactions, including anaphylactic reactions, angioedema and exfoliative skin conditions including Stevens-Johnson syndrome and erythema multiforme have been observed for DPP-4 inhibitors and have been spontaneously reported for alogliptin in the post-marketing setting.
Vipidia har ingen kendt virkning på evnen til at køre bil og betjene maskiner. 
Vipidia is not known to affect your ability to drive and use machines.
Data fra studier med metformin, pioglitazon (thiazolidindion), voglibose (alfa-glukosidasehæmmer) og glyburid (sulfonylurinstof) har ikke påvist klinisk relevante farmakokinetiske interaktioner. 
Results from studies with metformin, pioglitazone (thiazolidinedione), voglibose (alpha-glucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions.
Alogliptins farmakokinetik hos børn og unge under 18 år er endnu ikke klarlagt. 
The pharmacokinetics of alogliptin in children and adolescents < 18 years old has not been established.
Endvidere blev der udført et prospektivt, randomiseret, kardiovaskulært sikkerhedsendepunktsstudie med 5.380 patienter med høj underliggende kardiovaskulær risiko for at undersøge virkningen af alogliptin sammenlignet med placebo (i tillæg til standardbehandling) på større utilsigtede kardiovaskulære hændelser (MACE), herunder tid til den første forekomst af enhver hændelse i kombinationen af kardiovaskulær død, ikke-dødeligt myokardieinfarkt og ikke-dødelig apopleksi hos patienter med en nylig (15 til 90 dage) akut koronar hændelse. 
In addition, a prospective randomised cardiovascular outcomes safety study was conducted with 5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event.